REDWOOD CITY, Calif. & MUNICH--(BUSINESS WIRE)--The results of BeLieVeR-HIFi trial, the first double-blinded, randomized, controlled clinical trial to assess the impact of the Zephyr® Endobronchial Valve (EBV) for the treatment of emphysema, were presented today at the 2014 European Respiratory Society Conference in Munich by Nicholas S. Hopkinson, M.D., of The Royal Brompton & Harefield NHS Foundation Trust in London.
In the study, the third randomized clinical trial of the Zephyr device, patients with emphysema receiving the valves demonstrated statistically and clinically significant improvements in lung function, gas trapping and gas exchange, as well as exercise capacity measured on a cycle ergometer. The mean improvement in FEV1, a measure of pulmonary function, was 25% in treated patients. In addition, the procedure showed an acceptable safety profile, with clinically significant improvements in walking distance and quality of life.
Help employers find you! Check out all the jobs and post your resume.